Akers Biosciences, Inc. Director/PDMR Shareholding (7588L)
28 Diciembre 2018 - 9:45AM
UK Regulatory
TIDMAKR
RNS Number : 7588L
Akers Biosciences, Inc.
28 December 2018
December 28, 2018
Akers Biosciences, Inc.
Director/PDMR Shareholding
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the
"Company" or "Akers Bio"), a developer of rapid health information
technologies, announces that, pursuant to the employment agreement
between the Company and Howard R. Yeaton (Chief Executive Officer
and Interim Chief Financial Officer of the Company) announced on
October 12, 2018 which, following completion of the reverse stock
split announced on November 16, 2018, provides for a monthly grant
of 3,750 unrestricted shares of common stock of no par value
("Common Shares") pursuant to the Company's 2017 Equity Incentive
Plan (the "Plan"), the Company has issued to Mr. Yeaton 7,500
Common Shares in respect of the share obligation for the months of
October and November, 2018. These shares had a fair value per
Common Share as at October 31, 2018 and November 30, 2018 of $2.80
and $1.51, respectively.
The Company will apply for the 7,500 Common Shares to be
admitted to trading on AIM ("Admission") and Admission is expected
to occur on January 7, 2019. Following Admission, the Company's
issued share capital will consist of 12,482,708 Common Shares with
no Common Shares held in treasury. This figure may therefore be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the FCA's Disclosure Guidance and Transparency Rules.
Inquiries:
Akers Biosciences, Inc.
Howard R. Yeaton, Chief Executive Officer and Interim Chief
Financial Officer
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Ed Frisby / Scott Mathieson (Corporate Finance)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7390 0234
Email: akers@vigocomms.com
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com.
Cautionary Note Regarding Forward-Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements reflect the Company's expectations about its future
operating results, performance and opportunities that involve
substantial risks and uncertainties. Such statements may include,
without limitation, statements with respect to the Company's plans,
compliance with the requirements of various regulatory agencies and
certain NASDAQ Stock Market listing rules, objectives, projections,
expectations and intentions and other statements identified by
words such as "projects," "may," "will," "could," "would," "should,
" "believes," "expects," "anticipates," "estimates," "intends,"
"plans," "potential" or similar expressions, as they relate to the
Company, its subsidiaries, or its management. These statements are
based upon the current beliefs and expectations of the Company's
management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the
Securities and Exchange Commission. Actual results, performance,
prospects, and opportunities to may differ materially from those
set forth in, or implied by, the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which
are beyond the Company's control). The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable law.
The information communicated in this announcement is inside
information for the purposes of Article 7 of Regulation
596/2014.
APPENDIX
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Howard R. Yeaton
------------------------------- -------------------------------------
2. Reason for the Notification
----------------------------------------------------------------------
a) Position/status PDMR - Chief Executive Officer and
Interim Chief Financial Officer
------------------------------- -------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- -------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Akers Biosciences, Inc
------------------------------- -------------------------------------
b) LEI 213800CSKAC96ELS4K25
------------------------------- -------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description of the
Financial instrument, Common Shares of no par value
type of instrument
Identification code US00973E3009
------------------------------- -------------------------------------
b) Nature of the transaction Issuance of Common Shares
------------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
295 cents 3,750
152 cents 3,750
----------
------------------------------- -------------------------------------
d) Aggregated information: 3,750 ordinary shares at a price of
* Aggregated volume 295 cents for the month of October
2018
3,750 ordinary shares at a price of
* Price 152 cents for the month of November
2018
------------------------------- -------------------------------------
e) Date of the transaction December 27, 2018
------------------------------- -------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
(XLON) / Nasdaq, USA
------------------------------- -------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFESFIAFASEDE
(END) Dow Jones Newswires
December 28, 2018 10:45 ET (15:45 GMT)
Akers Biosciences (LSE:AKR)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Akers Biosciences (LSE:AKR)
Gráfica de Acción Histórica
De May 2023 a May 2024